Patents Assigned to Aminex Therapeutics
-
Patent number: 11865095Abstract: Provided herein are combinations comprising difluoromethylornithine (DFMO), or an ionic form thereof, and a compound of the following structural formula: or a protonated form thereof, wherein values for the variables (e.g., a, b, c, d, e, n, R1, R2, X) are described herein. The combinations can provide combination drug therapy in a single pharmaceutical dosage form, and be used, for example, for the treatment of cancer.Type: GrantFiled: September 30, 2021Date of Patent: January 9, 2024Assignee: Aminex Therapeutics, Inc.Inventor: Mark R. Burns
-
Patent number: 11395834Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.Type: GrantFiled: March 18, 2020Date of Patent: July 26, 2022Assignee: Aminex Therapeutics, Inc.Inventor: Mark R Burns
-
Patent number: 10632145Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.Type: GrantFiled: March 20, 2017Date of Patent: April 28, 2020Assignee: Aminex Therapeutics, Inc.Inventor: Mark R Burns
-
Publication number: 20190008892Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.Type: ApplicationFiled: March 20, 2017Publication date: January 10, 2019Applicant: AMINEX THERAPEUTICS INC.Inventor: Mark R Burns
-
Publication number: 20130164328Abstract: This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to H. Pylori infection together with prevention of pregnancy. With a small molecule drug, used in combination with DFMO, the pharmacological manipulation of polyamine levels for therapeutic benefit in various disease states is possible.Type: ApplicationFiled: February 20, 2013Publication date: June 27, 2013Applicants: Lankenau Institute For Medical Research, Aminex TherapeuticsInventors: Aminex Therapeutics, Lankenau Institute For Medical Research
-
Publication number: 20110256161Abstract: This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to H. Pylori infection together with prevention of pregnancy. With a small molecule drug, used in combination with DFMO, the pharmacological manipulation of polyamine levels for therapeutic benefit in various disease states is possible.Type: ApplicationFiled: April 19, 2011Publication date: October 20, 2011Applicant: AMINEX THERAPEUTICS INC.Inventors: MARK R. BURNS, SUSAN K. GILMOUR, THOMAS G. O'BRIEN
-
Patent number: RE43327Abstract: The disclosed invention provides new polyamine analogs and derivatives containing a hydrophobic region and a polyamine region as well as methods and compositions for their use.Type: GrantFiled: January 8, 2002Date of Patent: April 24, 2012Assignee: Aminex Therapeutics, Inc.Inventors: Mark R. Burns, Gerard F. Graminski, Nand Baindur